OptiNose, Inc. (OPTN) Analysts See $-0.68 EPS

November 10, 2018 - By Hannah Black

Analysts expect OptiNose, Inc. (NASDAQ:OPTN) to report $-0.68 EPS on November, 26.They anticipate $3.55 EPS change or 83.92 % from last quarter’s $-4.23 EPS. After having $-0.64 EPS previously, OptiNose, Inc.’s analysts see 6.25 % EPS growth. The stock decreased 1.81% or $0.2 during the last trading session, reaching $10.87. About 121,683 shares traded. OptiNose, Inc. (NASDAQ:OPTN) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company has market cap of $448.14 million. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It currently has negative earnings. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc.

More recent OptiNose, Inc. (NASDAQ:OPTN) news were published by: Globenewswire.com which released: “Optinose to Report Third Quarter 2018 Financial Results and Corporate Updates on November 13, 2018” on October 31, 2018. Also Globenewswire.com published the news titled: “Detailed Research: Economic Perspectives on Caseys General Stores, Evolus, OptiNose, Xunlei, Molina Healthcare …” on October 22, 2018. Seekingalpha.com‘s news article titled: “CVS Health Is Still A Buy – Cramer’s Lightning Round (10/11/18)” with publication date: October 12, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: